SCHEMBL18349751

SCHEMBL18349751

CC(=O)OCC1OC(Br)C(N2C(=O)c3c(Cl)c(Cl)c(Cl)c(Cl)c3C2=O)[C@@H](C)[C@H]1OC(C)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ CA12 O43570 10/20 0.39
▸ CA1 P00915 10/20 0.39
▸ CA2 P00918 10/20 0.39
▸ CA4 P22748 2/20 0.39
▸ CA5A P35218 2/20 0.39
▸ CA7 P43166 2/20 0.39
▸ CA5B Q9Y2D0 2/20 0.39
▸ TSHR P16473 1/20 0.38
▸ CA9 Q16790 8/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ CYP2D6 P10635 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16392969 0.91 TSHR (0.42) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL18349742 0.88 THRB (0.42) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL18349750 0.84 LMNA (0.38) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL5973544 0.82 THRB (0.45) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL25346209 0.81 THRB (0.46) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL16392960 0.81 THRB (0.46) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL5973361 0.81 THRB (0.46) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL22559758 0.77 TSHR (0.39) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL16392956 0.77 TSHR (0.39) THRBLMNASMN1; SMN2HIF1ACA12
SCHEMBL25985225 0.77 TSHR (0.39) THRBLMNASMN1; SMN2HIF1ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160376585-A1 OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION BANK OF AMERICA, N.A. 2016-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376585-A1 OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION IGF2R, IRS1, INSR THRB 848/4885LMNA 587/4885SMN1; SMN2 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback